AustralieFrV1, PubMed, Curation, bibRecord, 000738

Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A TransPORTEC initiative.

Identifieur interne : 000738 ( PubMed/Curation ); précédent : 000737; suivant : 000739

Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A TransPORTEC initiative.

Auteurs : R J Edmondson [Royaume-Uni] ; E J Crosbie [Royaume-Uni] ; M. Nickkho-Amiry [Royaume-Uni] ; A. Kaufmann [Royaume-Uni] ; E. Stelloo ; H W Nijman [Pays-Bas] ; A. Leary [France] ; A. Auguste [France] ; L. Mileshkin [Australie] ; P. Pollock [Australie] ; H J Mackay [Canada] ; M E Powell [Royaume-Uni] ; T. Bosse ; C L Creutzberg [Pays-Bas] ; H C Kitchener [Royaume-Uni]

Source :

Gynecologic oncology [ 1095-6859 ] ; 2017.

RBID : pubmed:28511869

Descripteurs français

English descriptors

Abstract

The morphological classification of high-risk endometrial cancer is of limited prognostic value. Recent attempts to stratify tumours according to molecular signatures have shown considerable promise. Here we attempted to further refine molecular classifications using markers of the p53 pathway.

DOI: 10.1016/j.ygyno.2017.05.014
PubMed: 28511869

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000741

Links to Exploration step

pubmed:28511869

Curation

No country items

E. Stelloo

<affiliation><nlm:affiliation>Department of Pathology, Leiden University Medical Center, Leiden, The Netherland.</nlm:affiliation>
<wicri:noCountry code="subField">The Netherland</wicri:noCountry>
</affiliation>

T. Bosse

<affiliation><nlm:affiliation>Department of Pathology, Leiden University Medical Center, Leiden, The Netherland.</nlm:affiliation>
<wicri:noCountry code="subField">The Netherland</wicri:noCountry>
</affiliation>

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A TransPORTEC initiative.</title>
<author><name sortKey="Edmondson, R J" sort="Edmondson, R J" uniqKey="Edmondson R" first="R J" last="Edmondson">R J Edmondson</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Molecular and Clinical Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, St Mary's Hospital, Manchester, UK; Department of Obstetrics and Gynaecology, Manchester Academic Health Science Centre, St Mary's Hospital, Central Manchester NHS Foundation Trust, Manchester Academic Health Science Centre, Level 5, Research, Oxford Road, Manchester, UK. Electronic address: richard.edmondson@manchester.ac.uk.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Division of Molecular and Clinical Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, St Mary's Hospital, Manchester, UK; Department of Obstetrics and Gynaecology, Manchester Academic Health Science Centre, St Mary's Hospital, Central Manchester NHS Foundation Trust, Manchester Academic Health Science Centre, Level 5, Research, Oxford Road, Manchester</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Crosbie, E J" sort="Crosbie, E J" uniqKey="Crosbie E" first="E J" last="Crosbie">E J Crosbie</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Molecular and Clinical Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, St Mary's Hospital, Manchester, UK; Department of Obstetrics and Gynaecology, Manchester Academic Health Science Centre, St Mary's Hospital, Central Manchester NHS Foundation Trust, Manchester Academic Health Science Centre, Level 5, Research, Oxford Road, Manchester, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Division of Molecular and Clinical Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, St Mary's Hospital, Manchester, UK; Department of Obstetrics and Gynaecology, Manchester Academic Health Science Centre, St Mary's Hospital, Central Manchester NHS Foundation Trust, Manchester Academic Health Science Centre, Level 5, Research, Oxford Road, Manchester</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Nickkho Amiry, M" sort="Nickkho Amiry, M" uniqKey="Nickkho Amiry M" first="M" last="Nickkho-Amiry">M. Nickkho-Amiry</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Molecular and Clinical Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, St Mary's Hospital, Manchester, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Division of Molecular and Clinical Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, St Mary's Hospital, Manchester</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kaufmann, A" sort="Kaufmann, A" uniqKey="Kaufmann A" first="A" last="Kaufmann">A. Kaufmann</name>
<affiliation wicri:level="1"><nlm:affiliation>Northern Institute of Cancer Research, Newcastle University, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Northern Institute of Cancer Research, Newcastle University</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Stelloo, E" sort="Stelloo, E" uniqKey="Stelloo E" first="E" last="Stelloo">E. Stelloo</name>
<affiliation><nlm:affiliation>Department of Pathology, Leiden University Medical Center, Leiden, The Netherland.</nlm:affiliation>
<wicri:noCountry code="subField">The Netherland</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Nijman, H W" sort="Nijman, H W" uniqKey="Nijman H" first="H W" last="Nijman">H W Nijman</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Gynecology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Gynecology, University of Groningen, University Medical Center Groningen, Groningen</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Leary, A" sort="Leary, A" uniqKey="Leary A" first="A" last="Leary">A. Leary</name>
<affiliation wicri:level="1"><nlm:affiliation>INSERM U981, Department of Medicine, Gynecology Unit, Gustave Roussy, Villejuif, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM U981, Department of Medicine, Gynecology Unit, Gustave Roussy, Villejuif</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Auguste, A" sort="Auguste, A" uniqKey="Auguste A" first="A" last="Auguste">A. Auguste</name>
<affiliation wicri:level="1"><nlm:affiliation>INSERM U981, Department of Medicine, Gynecology Unit, Gustave Roussy, Villejuif, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM U981, Department of Medicine, Gynecology Unit, Gustave Roussy, Villejuif</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Mileshkin, L" sort="Mileshkin, L" uniqKey="Mileshkin L" first="L" last="Mileshkin">L. Mileshkin</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Division of Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Pollock, P" sort="Pollock, P" uniqKey="Pollock P" first="P" last="Pollock">P. Pollock</name>
<affiliation wicri:level="1"><nlm:affiliation>Queensland University of Technology, (QUT), Translational Research Institute, Brisbane, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Queensland University of Technology, (QUT), Translational Research Institute, Brisbane</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Mackay, H J" sort="Mackay, H J" uniqKey="Mackay H" first="H J" last="Mackay">H J Mackay</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Princess Margaret Hospital/University Health Network, University of Toronto, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Princess Margaret Hospital/University Health Network, University of Toronto</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Powell, M E" sort="Powell, M E" uniqKey="Powell M" first="M E" last="Powell">M E Powell</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Clinical Oncology, Barts Health NHS Trust, London, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Clinical Oncology, Barts Health NHS Trust, London</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Bosse, T" sort="Bosse, T" uniqKey="Bosse T" first="T" last="Bosse">T. Bosse</name>
<affiliation><nlm:affiliation>Department of Pathology, Leiden University Medical Center, Leiden, The Netherland.</nlm:affiliation>
<wicri:noCountry code="subField">The Netherland</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Creutzberg, C L" sort="Creutzberg, C L" uniqKey="Creutzberg C" first="C L" last="Creutzberg">C L Creutzberg</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Clinical Oncology, Leiden University Medical Center, Leiden</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kitchener, H C" sort="Kitchener, H C" uniqKey="Kitchener H" first="H C" last="Kitchener">H C Kitchener</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Molecular and Clinical Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, St Mary's Hospital, Manchester, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Division of Molecular and Clinical Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, St Mary's Hospital, Manchester</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2017">2017</date>
<idno type="RBID">pubmed:28511869</idno>
<idno type="pmid">28511869</idno>
<idno type="doi">10.1016/j.ygyno.2017.05.014</idno>
<idno type="wicri:Area/PubMed/Corpus">000741</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000741</idno>
<idno type="wicri:Area/PubMed/Curation">000738</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000738</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A TransPORTEC initiative.</title>
<author><name sortKey="Edmondson, R J" sort="Edmondson, R J" uniqKey="Edmondson R" first="R J" last="Edmondson">R J Edmondson</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Molecular and Clinical Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, St Mary's Hospital, Manchester, UK; Department of Obstetrics and Gynaecology, Manchester Academic Health Science Centre, St Mary's Hospital, Central Manchester NHS Foundation Trust, Manchester Academic Health Science Centre, Level 5, Research, Oxford Road, Manchester, UK. Electronic address: richard.edmondson@manchester.ac.uk.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Division of Molecular and Clinical Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, St Mary's Hospital, Manchester, UK; Department of Obstetrics and Gynaecology, Manchester Academic Health Science Centre, St Mary's Hospital, Central Manchester NHS Foundation Trust, Manchester Academic Health Science Centre, Level 5, Research, Oxford Road, Manchester</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Crosbie, E J" sort="Crosbie, E J" uniqKey="Crosbie E" first="E J" last="Crosbie">E J Crosbie</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Molecular and Clinical Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, St Mary's Hospital, Manchester, UK; Department of Obstetrics and Gynaecology, Manchester Academic Health Science Centre, St Mary's Hospital, Central Manchester NHS Foundation Trust, Manchester Academic Health Science Centre, Level 5, Research, Oxford Road, Manchester, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Division of Molecular and Clinical Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, St Mary's Hospital, Manchester, UK; Department of Obstetrics and Gynaecology, Manchester Academic Health Science Centre, St Mary's Hospital, Central Manchester NHS Foundation Trust, Manchester Academic Health Science Centre, Level 5, Research, Oxford Road, Manchester</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Nickkho Amiry, M" sort="Nickkho Amiry, M" uniqKey="Nickkho Amiry M" first="M" last="Nickkho-Amiry">M. Nickkho-Amiry</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Molecular and Clinical Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, St Mary's Hospital, Manchester, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Division of Molecular and Clinical Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, St Mary's Hospital, Manchester</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kaufmann, A" sort="Kaufmann, A" uniqKey="Kaufmann A" first="A" last="Kaufmann">A. Kaufmann</name>
<affiliation wicri:level="1"><nlm:affiliation>Northern Institute of Cancer Research, Newcastle University, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Northern Institute of Cancer Research, Newcastle University</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Stelloo, E" sort="Stelloo, E" uniqKey="Stelloo E" first="E" last="Stelloo">E. Stelloo</name>
<affiliation><nlm:affiliation>Department of Pathology, Leiden University Medical Center, Leiden, The Netherland.</nlm:affiliation>
<wicri:noCountry code="subField">The Netherland</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Nijman, H W" sort="Nijman, H W" uniqKey="Nijman H" first="H W" last="Nijman">H W Nijman</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Gynecology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Gynecology, University of Groningen, University Medical Center Groningen, Groningen</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Leary, A" sort="Leary, A" uniqKey="Leary A" first="A" last="Leary">A. Leary</name>
<affiliation wicri:level="1"><nlm:affiliation>INSERM U981, Department of Medicine, Gynecology Unit, Gustave Roussy, Villejuif, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM U981, Department of Medicine, Gynecology Unit, Gustave Roussy, Villejuif</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Auguste, A" sort="Auguste, A" uniqKey="Auguste A" first="A" last="Auguste">A. Auguste</name>
<affiliation wicri:level="1"><nlm:affiliation>INSERM U981, Department of Medicine, Gynecology Unit, Gustave Roussy, Villejuif, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM U981, Department of Medicine, Gynecology Unit, Gustave Roussy, Villejuif</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Mileshkin, L" sort="Mileshkin, L" uniqKey="Mileshkin L" first="L" last="Mileshkin">L. Mileshkin</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Division of Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Pollock, P" sort="Pollock, P" uniqKey="Pollock P" first="P" last="Pollock">P. Pollock</name>
<affiliation wicri:level="1"><nlm:affiliation>Queensland University of Technology, (QUT), Translational Research Institute, Brisbane, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Queensland University of Technology, (QUT), Translational Research Institute, Brisbane</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Mackay, H J" sort="Mackay, H J" uniqKey="Mackay H" first="H J" last="Mackay">H J Mackay</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Princess Margaret Hospital/University Health Network, University of Toronto, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Princess Margaret Hospital/University Health Network, University of Toronto</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Powell, M E" sort="Powell, M E" uniqKey="Powell M" first="M E" last="Powell">M E Powell</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Clinical Oncology, Barts Health NHS Trust, London, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Clinical Oncology, Barts Health NHS Trust, London</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Bosse, T" sort="Bosse, T" uniqKey="Bosse T" first="T" last="Bosse">T. Bosse</name>
<affiliation><nlm:affiliation>Department of Pathology, Leiden University Medical Center, Leiden, The Netherland.</nlm:affiliation>
<wicri:noCountry code="subField">The Netherland</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Creutzberg, C L" sort="Creutzberg, C L" uniqKey="Creutzberg C" first="C L" last="Creutzberg">C L Creutzberg</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Clinical Oncology, Leiden University Medical Center, Leiden</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kitchener, H C" sort="Kitchener, H C" uniqKey="Kitchener H" first="H C" last="Kitchener">H C Kitchener</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Molecular and Clinical Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, St Mary's Hospital, Manchester, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Division of Molecular and Clinical Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, St Mary's Hospital, Manchester</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Gynecologic oncology</title>
<idno type="eISSN">1095-6859</idno>
<imprint><date when="2017" type="published">2017</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenocarcinoma, Clear Cell (genetics)</term>
<term>Adenocarcinoma, Clear Cell (metabolism)</term>
<term>Adenocarcinoma, Clear Cell (mortality)</term>
<term>Adenocarcinoma, Clear Cell (pathology)</term>
<term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Carcinoma, Endometrioid (genetics)</term>
<term>Carcinoma, Endometrioid (metabolism)</term>
<term>Carcinoma, Endometrioid (mortality)</term>
<term>Carcinoma, Endometrioid (pathology)</term>
<term>Cell Line, Tumor</term>
<term>Cyclin-Dependent Kinase Inhibitor p21 (metabolism)</term>
<term>Endometrial Neoplasms (genetics)</term>
<term>Endometrial Neoplasms (metabolism)</term>
<term>Endometrial Neoplasms (mortality)</term>
<term>Endometrial Neoplasms (pathology)</term>
<term>Female</term>
<term>Gene Silencing</term>
<term>Humans</term>
<term>Immunohistochemistry</term>
<term>Middle Aged</term>
<term>Mutation</term>
<term>Neoplasm Grading</term>
<term>Neoplasm Invasiveness</term>
<term>Neoplasms, Cystic, Mucinous, and Serous (genetics)</term>
<term>Neoplasms, Cystic, Mucinous, and Serous (metabolism)</term>
<term>Neoplasms, Cystic, Mucinous, and Serous (mortality)</term>
<term>Neoplasms, Cystic, Mucinous, and Serous (pathology)</term>
<term>Phosphoproteins</term>
<term>Prognosis</term>
<term>Proportional Hazards Models</term>
<term>Proto-Oncogene Proteins c-mdm2 (metabolism)</term>
<term>Signal Transduction</term>
<term>Transcription Factors (metabolism)</term>
<term>Tumor Suppressor Protein p53 (genetics)</term>
<term>Tumor Suppressor Protein p53 (metabolism)</term>
<term>Tumor Suppressor Proteins (metabolism)</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Adénocarcinome à cellules claires (anatomopathologie)</term>
<term>Adénocarcinome à cellules claires (génétique)</term>
<term>Adénocarcinome à cellules claires (mortalité)</term>
<term>Adénocarcinome à cellules claires (métabolisme)</term>
<term>Carcinome endométrioïde (anatomopathologie)</term>
<term>Carcinome endométrioïde (génétique)</term>
<term>Carcinome endométrioïde (mortalité)</term>
<term>Carcinome endométrioïde (métabolisme)</term>
<term>Extinction de l'expression des gènes</term>
<term>Facteurs de transcription (métabolisme)</term>
<term>Femelle</term>
<term>Grading des tumeurs</term>
<term>Humains</term>
<term>Immunohistochimie</term>
<term>Inhibiteur p21 de kinase cycline-dépendante (métabolisme)</term>
<term>Invasion tumorale</term>
<term>Jeune adulte</term>
<term>Lignée cellulaire tumorale</term>
<term>Modèles de hasards proportionnels</term>
<term>Mutation</term>
<term>Phosphoprotéines</term>
<term>Pronostic</term>
<term>Protéine p53 suppresseur de tumeur (génétique)</term>
<term>Protéine p53 suppresseur de tumeur (métabolisme)</term>
<term>Protéines proto-oncogènes c-mdm2 (métabolisme)</term>
<term>Protéines suppresseurs de tumeurs (métabolisme)</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Transduction du signal</term>
<term>Tumeurs de l'endomètre (anatomopathologie)</term>
<term>Tumeurs de l'endomètre (génétique)</term>
<term>Tumeurs de l'endomètre (mortalité)</term>
<term>Tumeurs de l'endomètre (métabolisme)</term>
<term>Tumeurs kystiques, mucineuses et séreuses (anatomopathologie)</term>
<term>Tumeurs kystiques, mucineuses et séreuses (génétique)</term>
<term>Tumeurs kystiques, mucineuses et séreuses (mortalité)</term>
<term>Tumeurs kystiques, mucineuses et séreuses (métabolisme)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Tumor Suppressor Protein p53</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Cyclin-Dependent Kinase Inhibitor p21</term>
<term>Proto-Oncogene Proteins c-mdm2</term>
<term>Transcription Factors</term>
<term>Tumor Suppressor Protein p53</term>
<term>Tumor Suppressor Proteins</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Adénocarcinome à cellules claires</term>
<term>Carcinome endométrioïde</term>
<term>Tumeurs de l'endomètre</term>
<term>Tumeurs kystiques, mucineuses et séreuses</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Adenocarcinoma, Clear Cell</term>
<term>Carcinoma, Endometrioid</term>
<term>Endometrial Neoplasms</term>
<term>Neoplasms, Cystic, Mucinous, and Serous</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Adénocarcinome à cellules claires</term>
<term>Carcinome endométrioïde</term>
<term>Protéine p53 suppresseur de tumeur</term>
<term>Tumeurs de l'endomètre</term>
<term>Tumeurs kystiques, mucineuses et séreuses</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Adenocarcinoma, Clear Cell</term>
<term>Carcinoma, Endometrioid</term>
<term>Endometrial Neoplasms</term>
<term>Neoplasms, Cystic, Mucinous, and Serous</term>
</keywords>
<keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Adenocarcinoma, Clear Cell</term>
<term>Carcinoma, Endometrioid</term>
<term>Endometrial Neoplasms</term>
<term>Neoplasms, Cystic, Mucinous, and Serous</term>
</keywords>
<keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Adénocarcinome à cellules claires</term>
<term>Carcinome endométrioïde</term>
<term>Tumeurs de l'endomètre</term>
<term>Tumeurs kystiques, mucineuses et séreuses</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Adénocarcinome à cellules claires</term>
<term>Carcinome endométrioïde</term>
<term>Facteurs de transcription</term>
<term>Inhibiteur p21 de kinase cycline-dépendante</term>
<term>Protéine p53 suppresseur de tumeur</term>
<term>Protéines proto-oncogènes c-mdm2</term>
<term>Protéines suppresseurs de tumeurs</term>
<term>Tumeurs de l'endomètre</term>
<term>Tumeurs kystiques, mucineuses et séreuses</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Adenocarcinoma, Clear Cell</term>
<term>Carcinoma, Endometrioid</term>
<term>Endometrial Neoplasms</term>
<term>Neoplasms, Cystic, Mucinous, and Serous</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Cell Line, Tumor</term>
<term>Female</term>
<term>Gene Silencing</term>
<term>Humans</term>
<term>Immunohistochemistry</term>
<term>Middle Aged</term>
<term>Mutation</term>
<term>Neoplasm Grading</term>
<term>Neoplasm Invasiveness</term>
<term>Phosphoproteins</term>
<term>Prognosis</term>
<term>Proportional Hazards Models</term>
<term>Signal Transduction</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Extinction de l'expression des gènes</term>
<term>Femelle</term>
<term>Grading des tumeurs</term>
<term>Humains</term>
<term>Immunohistochimie</term>
<term>Invasion tumorale</term>
<term>Jeune adulte</term>
<term>Lignée cellulaire tumorale</term>
<term>Modèles de hasards proportionnels</term>
<term>Mutation</term>
<term>Phosphoprotéines</term>
<term>Pronostic</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Transduction du signal</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The morphological classification of high-risk endometrial cancer is of limited prognostic value. Recent attempts to stratify tumours according to molecular signatures have shown considerable promise. Here we attempted to further refine molecular classifications using markers of the p53 pathway.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28511869</PMID>
<DateCreated><Year>2017</Year>
<Month>05</Month>
<Day>17</Day>
</DateCreated>
<DateCompleted><Year>2017</Year>
<Month>07</Month>
<Day>24</Day>
</DateCompleted>
<DateRevised><Year>2017</Year>
<Month>07</Month>
<Day>24</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-6859</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>146</Volume>
<Issue>2</Issue>
<PubDate><Year>2017</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>Gynecologic oncology</Title>
<ISOAbbreviation>Gynecol. Oncol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A TransPORTEC initiative.</ArticleTitle>
<Pagination><MedlinePgn>327-333</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S0090-8258(17)30853-3</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ygyno.2017.05.014</ELocationID>
<Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The morphological classification of high-risk endometrial cancer is of limited prognostic value. Recent attempts to stratify tumours according to molecular signatures have shown considerable promise. Here we attempted to further refine molecular classifications using markers of the p53 pathway.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">We analysed the expression of p53 as well as three downstream markers of the p53 pathway, p21, mdm2 and phospho-p63 (pp63), by immunohistochemistry in a series of 114 endometrial cancers (86 endometrioid, 28 non-endometrioid subtype) with high-risk features (such as high tumour grade and deep myometrial invasion) and correlated results with clinical outcome. The Cancer Genome Atlas (TCGA) data were used to analyse TP63 mutations and copy-number alterations using cBioPortal. TP53 was silenced in two endometrial cancer cell lines to study its effect on p21 and p63.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">About half of the tumours showed a p53 mutant phenotype and there was a strong negative correlation with p21 expression. Being marker positive for pp63 or mdm2 was associated with a significantly increased likelihood of dying, [hazard ratios 5.93 (95% CI 2.37-7.27) and 7.48 (95% CI 3.04-9.39), respectively]. These findings were seen in both p53 wildtype and p53 mutant tumours. Only 11% of TCGA endometrial cancers had a functional TP63 alteration. Upon silencing of TP53, p21 expression was decreased in one cell line, but no effects on p63 were observed.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Markers of the p53 pathway improve stratification of endometrial cancers and provide novel insights into the role of this pathway in the disease.</AbstractText>
<CopyrightInformation>Copyright © 2017. Published by Elsevier Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Edmondson</LastName>
<ForeName>R J</ForeName>
<Initials>RJ</Initials>
<AffiliationInfo><Affiliation>Division of Molecular and Clinical Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, St Mary's Hospital, Manchester, UK; Department of Obstetrics and Gynaecology, Manchester Academic Health Science Centre, St Mary's Hospital, Central Manchester NHS Foundation Trust, Manchester Academic Health Science Centre, Level 5, Research, Oxford Road, Manchester, UK. Electronic address: richard.edmondson@manchester.ac.uk.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Crosbie</LastName>
<ForeName>E J</ForeName>
<Initials>EJ</Initials>
<AffiliationInfo><Affiliation>Division of Molecular and Clinical Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, St Mary's Hospital, Manchester, UK; Department of Obstetrics and Gynaecology, Manchester Academic Health Science Centre, St Mary's Hospital, Central Manchester NHS Foundation Trust, Manchester Academic Health Science Centre, Level 5, Research, Oxford Road, Manchester, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Nickkho-Amiry</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Division of Molecular and Clinical Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, St Mary's Hospital, Manchester, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kaufmann</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Northern Institute of Cancer Research, Newcastle University, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Stelloo</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>Department of Pathology, Leiden University Medical Center, Leiden, The Netherland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Nijman</LastName>
<ForeName>H W</ForeName>
<Initials>HW</Initials>
<AffiliationInfo><Affiliation>Department of Gynecology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Leary</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>INSERM U981, Department of Medicine, Gynecology Unit, Gustave Roussy, Villejuif, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Auguste</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>INSERM U981, Department of Medicine, Gynecology Unit, Gustave Roussy, Villejuif, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Mileshkin</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Division of Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Pollock</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Queensland University of Technology, (QUT), Translational Research Institute, Brisbane, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>MacKay</LastName>
<ForeName>H J</ForeName>
<Initials>HJ</Initials>
<AffiliationInfo><Affiliation>Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Princess Margaret Hospital/University Health Network, University of Toronto, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Powell</LastName>
<ForeName>M E</ForeName>
<Initials>ME</Initials>
<AffiliationInfo><Affiliation>Department of Clinical Oncology, Barts Health NHS Trust, London, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bosse</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
<AffiliationInfo><Affiliation>Department of Pathology, Leiden University Medical Center, Leiden, The Netherland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Creutzberg</LastName>
<ForeName>C L</ForeName>
<Initials>CL</Initials>
<AffiliationInfo><Affiliation>Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kitchener</LastName>
<ForeName>H C</ForeName>
<Initials>HC</Initials>
<AffiliationInfo><Affiliation>Division of Molecular and Clinical Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, St Mary's Hospital, Manchester, UK.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2017</Year>
<Month>05</Month>
<Day>13</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Gynecol Oncol</MedlineTA>
<NlmUniqueID>0365304</NlmUniqueID>
<ISSNLinking>0090-8258</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C493956">CDKN1A protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050759">Cyclin-Dependent Kinase Inhibitor p21</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010750">Phosphoproteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C495901">TP53 protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C115051">TP63 protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016159">Tumor Suppressor Protein p53</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D025521">Tumor Suppressor Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.3.2.27</RegistryNumber>
<NameOfSubstance UI="C497206">MDM2 protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.3.2.27</RegistryNumber>
<NameOfSubstance UI="D051736">Proto-Oncogene Proteins c-mdm2</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D018262" MajorTopicYN="N">Adenocarcinoma, Clear Cell</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018269" MajorTopicYN="N">Carcinoma, Endometrioid</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D050759" MajorTopicYN="N">Cyclin-Dependent Kinase Inhibitor p21</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016889" MajorTopicYN="N">Endometrial Neoplasms</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020868" MajorTopicYN="N">Gene Silencing</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D060787" MajorTopicYN="N">Neoplasm Grading</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009361" MajorTopicYN="N">Neoplasm Invasiveness</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018297" MajorTopicYN="N">Neoplasms, Cystic, Mucinous, and Serous</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010750" MajorTopicYN="N">Phosphoproteins</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051736" MajorTopicYN="N">Proto-Oncogene Proteins c-mdm2</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016159" MajorTopicYN="N">Tumor Suppressor Protein p53</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D025521" MajorTopicYN="N">Tumor Suppressor Proteins</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Endometrial cancer</Keyword>
<Keyword MajorTopicYN="N">L1CAM</Keyword>
<Keyword MajorTopicYN="N">Molecular profiling</Keyword>
<Keyword MajorTopicYN="N">Pole</Keyword>
<Keyword MajorTopicYN="N">Prognosis</Keyword>
<Keyword MajorTopicYN="N">p21</Keyword>
<Keyword MajorTopicYN="N">p53</Keyword>
<Keyword MajorTopicYN="N">pp63</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year>
<Month>03</Month>
<Day>02</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2017</Year>
<Month>05</Month>
<Day>09</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2017</Year>
<Month>5</Month>
<Day>18</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2017</Year>
<Month>7</Month>
<Day>25</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2017</Year>
<Month>5</Month>
<Day>18</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">28511869</ArticleId>
<ArticleId IdType="pii">S0090-8258(17)30853-3</ArticleId>
<ArticleId IdType="doi">10.1016/j.ygyno.2017.05.014</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000738 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000738 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:28511869
   |texte=   Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A TransPORTEC initiative.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:28511869" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a AustralieFrV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A TransPORTEC initiative.

Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A TransPORTEC initiative.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Curation

No country items

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki